Polypeptide Derivative of Metformin with the Combined Advantage of a Gene Carrier and Anticancer Activity-Reference-Cited by-同舟云学术

Polypeptide Derivative of Metformin with the Combined Advantage of a Gene Carrier and Anticancer Activity

Published:2019-09-23 Issue:10 Volume:5 Page:5159-5168
ISSN:2373-9878
Container-title:ACS Biomaterials Science & Engineering
language:en
Short-container-title:ACS Biomater. Sci. Eng.

Author:

Ramasamy Thiruganesh¹²,Ruttala Hima Bindu¹³,Kaliraj Kaliappan⁴,Poudel Kishwor¹,Jin Sung Giu⁵,Choi Han-Gon⁶,Ku Sae Kwang⁷,Yong Chul Soon¹,Kim Jong Oh¹^ORCID

Affiliation:

1. College of Pharmacy, Yeungnam University, 214-1, Dae-dong, Gyeongsan 712-749, Republic of Korea

2. Center for Ultrasound Molecular Imaging and Therapeutics, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States

3. Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States

4. College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P.R. China

5. Department of Pharmaceutical Engineering, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan, 31116, Republic of Korea

6. College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, 55, Hanyangdaehak-ro, Sangnok-gu, Ansan 426-791, Republic of Korea

7. College of Korean Medicine, Daegu Haany University, Gyeongsan 712-715, Republic of Korea

Funder

National Research Foundation of Korea

Publisher

American Chemical Society (ACS)

Subject

Biomedical Engineering,Biomaterials

Link

https://pubs.acs.org/doi/pdf/10.1021/acsbiomaterials.9b00982

Reference36 articles.

1. Metformin—mode of action and clinical implications for diabetes and cancer

2. Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1